Tango Therapeutics, Inc.
NASDAQ:TNGXBiotechnology
-$3.24 today
- Market cap
- $3.85B
- Beta
- 1.19
- P/E (TTM)
- -38.9
- EPS (TTM)
- -$0.75
Volume 1.81M
Average 3.67M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Tango Therapeutics, Inc.
NASDAQ:TNGX
Intrinsic Alpha fair value
Locked
Current Price
$22.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +35.9% | +68.1% (5yr)5 analysts |
| Net Income | N/A | N/A | N/A | N/A5 analysts |
| EBIT | N/A | N/A | N/A | N/A5 analysts |
Analysis
Recent growth has been strongest in Revenue at +35.9% over three years. Forward estimates point to Revenue at +68.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Revolution Medicines, Inc. NASDAQ:RVMD | $37.26B | $172.29 | Not rated | -23.3 | +126.05% |
Erasca, Inc. NASDAQ:ERAS | $5.48B | $15.66 | Not rated | -15.3 | +415.22% |
Relay Therapeutics, Inc. NASDAQ:RLAY | $4.00B | $18.09 | Not rated | -10.5 | +150.95% |
IDEAYA Biosciences, Inc. NASDAQ:IDYA | $3.08B | $31.83 | Not rated | -19.5 | -21.01% |
Nurix Therapeutics, Inc. NASDAQ:NRIX | $1.69B | $15.48 | Undervalued | -6.4 | -5.09% |
Nuvation Bio Inc. NYSE:NUVB | $1.40B | $3.99 | Not rated | -12.8 | -46.71% |
C4 Therapeutics, Inc. NASDAQ:CCCC | $362.43M | $2.76 | Not rated | -4.9 | -2.40% |
Prelude Therapeutics Incorporated NASDAQ:PRLD | $275.32M | $3.45 | Not rated | -4.5 | +94.91% |
Foghorn Therapeutics Inc. NASDAQ:FHTX | $124.12M | $2.07 | Not rated | -3.8 | -63.37% |
Acrivon Therapeutics, Inc. Common Stock NASDAQ:ACRV | $62.14M | $1.45 | Not rated | -0.8 | -40.68% |
Continue the stock analysis
Jump to another research area for this company.